Trimeric Anti-Spike Antibodies for SARS-CoV-2 Variant Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current neutralizing antibodies and vaccines are ineffective against emerging SARS-CoV-2 variants due to immune escape mutations, particularly the B.1.351 and B.1.617.2 variants, necessitating the development of variant-resistant antibodies.
Innovation Solution
Development of antibodies and fragments thereof with specific CDR sequences that bind to the SARS-CoV-2 spike protein, particularly the receptor binding domain (RBD), and engineered into trimeric formats to enhance neutralization efficacy against variant strains.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current neutralizing antibodies and vaccines are used, then initial SARS-CoV-2 strains are effectively neutralized, but emerging variant strains (B.1.351, B.1.617.2) exhibit immune escape and reduced neutralization efficacy
Solution Approach 1:
The patent applies parameter changes by modifying the antibody structure through engineered CDR sequences (specific amino acid compositions in CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 regions) to alter binding characteristics. This enables the antibodies to maintain effective binding affinity across multiple SARS-CoV-2 variants while preserving neutralization capability against wild-type strains.
Solution Approach 2:
The patent achieves universality by designing antibodies with broad-spectrum activity against multiple SARS-CoV-2 variants including B.1.351, B.1.617.2, and other emerging strains. The engineered antibodies simultaneously provide neutralization of wild-type virus and resistance to variant escape mutations, making them versatile therapeutic agents for evolving viral threats.
2Reliability
If antibody concentration is increased to overcome immune escape, then neutralization potency increases, but therapeutic index and safety profile may be compromised
Solution Approach 1:
The patent resolves this contradiction through parameter changes in antibody structure (engineered CDR sequences) that increase binding affinity and neutralization potency at lower concentrations. This structural optimization allows effective neutralization of variants without requiring high antibody doses, thereby maintaining an favorable therapeutic index and safety profile.
3Ease of manufacture
If traditional antibody formats are used, then production and delivery are simplified, but neutralization potency against variants is insufficient
Solution Approach 1:
The patent maintains traditional antibody format (IgG structure with heavy and light chains) for ease of manufacture and delivery, while implementing parameter changes in the CDR regions to enhance neutralization potency. This approach achieves high potency against variants without complicating production processes or delivery mechanisms.
Data Source
AI summary
Provided are human antibodies and fragments thereof having binding specificity to the SARS-CoV-2 spike protein's receptor binding domain (RBD). The antibodies and fragments have strong affinity and potent neutralization ability against the SARS-CoV-2 virus and various mutant forms. Also provided are trimeric antibodies which have further enhanced neutralization capabilities. The antibodies and fragments thus may be used for preventing or treating SARS-CoV-2 viral infection or detecting the presence of the virus in a sample.